340B Drug Pricing Program — Discounted Drugs for Safety-Net Providers

The 340B Drug Pricing Program (42 U.S.C. § 256b) requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at significantly discounted prices — typically 25–50% below the average manufacturer price (see Pharmaceutical Import Rules) — to safety-net healthcare providers ("covered entities") serving low-income and uninsured patients. Created in 1992, the program's premise is straightforward: hospitals and clinics that serve disproportionate numbers of poor patients should be able to stretch their limited resources by purchasing drugs at the same deep discounts the government negotiates for other federal programs. There are now approximately 50,000+ covered entity sites participating in 340B — including federally qualified health centers, children's hospitals, critical access hospitals, disproportionate share hospitals, Ryan White HIV/AIDS clinics, and other safety-net providers — purchasing an estimated $53+ billion in discounted drugs annually (roughly 12% of all U.S. drug purchases by dollar volume). The program has become one of the most controversial areas of healthcare policy, with pharmaceutical companies arguing it has grown far beyond its original intent and safety-net providers arguing it is essential to their survival.

Current Law (2026)

Legal Authority

• 42 U.S.C. § 256b — Limitation on prices of drugs purchased by covered entities (manufacturers participating in Medicaid must offer 340B pricing to covered entities; statutory ceiling price = average manufacturer price minus the Medicaid unit rebate amount; HRSA administers the program; covered entities may not resell or divert 340B drugs; duplicate discounts prohibited)

How It Works

The 340B ceiling price is calculated as the Average Manufacturer Price (AMP) minus the Medicaid unit rebate amount (42 U.S.C. § 256b) — essentially the same discount the Medicaid program negotiates, applied to safety-net provider purchases. For brand-name drugs, this means a minimum 23.1% discount off AMP (the basic Medicaid rebate percentage), with additional discounts when a drug's price has increased faster than inflation. Manufacturer participation is mandatory for any company whose drugs are covered by Medicaid — virtually all of them. The statute defines specific eligible provider categories: federally qualified health centers (FQHCs), disproportionate share hospitals (DSH hospitals), children's hospitals, critical access hospitals, sole community hospitals, free-standing cancer hospitals, Ryan White HIV/AIDS clinics, hemophilia treatment centers, STD and tuberculosis clinics, black lung clinics, Title X family planning clinics, and urban Indian health organizations — each must register with HRSA's OPAIS system and meet specific qualifying criteria.

Originally, 340B covered entities dispensed drugs through their own in-house pharmacies. A 2010 HRSA guidance allowed contract pharmacies — retail chains like CVS and Walgreens — to dispense 340B drugs on covered entities' behalf, dramatically expanding the program's reach but creating the central policy controversy: a hospital can purchase drugs at 340B prices and have them dispensed by a commercial pharmacy miles away to commercially insured patients, generating revenue for both the hospital and pharmacy with no guarantee savings reach patients. Since 2020, major manufacturers (AstraZeneca, Novartis, Sanofi, Eli Lilly) have restricted 340B contract pharmacy arrangements, arguing the program has exceeded its intent; HRSA has declared these restrictions unlawful; federal circuit courts have split. The statute's patient definition is imprecise — HRSA guidance requires a documented healthcare relationship with the covered entity, but the broad definition has allowed coverage of commercially insured patients. A covered entity may not receive both a 340B discount and a Medicaid rebate on the same drug for the same patient (the duplicate discount prohibition), but enforcing this is complex when contract pharmacies also serve Medicaid patients.

How It Affects You

If you're a patient at a safety-net hospital, FQHC, or Ryan White clinic: 340B helps your provider stretch limited resources — but there's no federal requirement that savings pass directly to you as lower drug prices at the pharmacy counter. What 340B actually does for you:

• Cross-subsidizes uncompensated care: The "spread" between what a hospital pays for 340B drugs and what it bills insurance funds care for patients who can't pay — the program's stated purpose
• Enables low-cost pharmacy programs: Many FQHCs and safety-net clinics run on-site pharmacy programs where 340B savings allow sliding-scale copays for chronic disease medications — insulin, HIV antiretrovirals, inhalers — that would otherwise be unaffordable. Ask your clinic whether they operate an in-house 340B pharmacy
• What you can't assume: If your covered entity uses a commercial contract pharmacy (a retail CVS or Walgreens), there's no guarantee you're getting a lower price. The 340B savings go to the hospital, not necessarily to you at the counter

If you're a safety-net hospital, FQHC, or covered entity administrator: 340B is one of the most complex programs you administer and one of the most critical revenue sources. For large DSH hospitals, 340B revenues can reach hundreds of millions of dollars annually — an amount that, if lost to compliance failure, could threaten your ability to serve uninsured patients.

Critical compliance requirements:

• Registration: Every covered entity site must be registered in HRSA's 340B OPAIS (Online Registration and Information System) at hrsa.gov/opa — including satellites and contract pharmacy arrangements. Unregistered sites cannot legally dispense 340B drugs
• Patient definition: 340B drugs can only be dispensed to your patients — someone receiving healthcare services from your covered entity with a documented treatment relationship. HRSA guidance defines this carefully; a person who merely fills a prescription at an affiliated retail pharmacy without a care relationship doesn't qualify
• Duplicate discount prohibition: You cannot bill Medicaid for a 340B drug and also collect the Medicaid manufacturer rebate on the same drug for the same patient. This requires precise claims tagging or carve-out of Medicaid claims from 340B purchases — one of the most common compliance failures that HRSA audits find
• Contract pharmacy restrictions: Since 2020, major manufacturers including AstraZeneca, Novartis, Sanofi, and Eli Lilly have restricted 340B pricing at contract pharmacies, arguing the program has exceeded its scope. HRSA has declared these restrictions unlawful; manufacturers have sued; federal circuit courts have split. Track the litigation through your General Counsel and HRSA's current enforcement notices at hrsa.gov/opa
• Audits: HRSA audits covered entities and manufacturers. Adverse findings can require repayment of overcharges and, for repeat violations, removal from the program. Maintain meticulous records of patient eligibility determinations, drug purchases, and dispensing records for at least 3 years

If you're a pharmaceutical manufacturer: Participation is mandatory if you're in Medicaid. Every 340B drug sale must be tracked and priced at or below the ceiling price (AMP minus unit rebate amount) — HRSA's OPAIS system publishes ceiling prices. HRSA can assess civil monetary penalties up to $5,000 per instance for overcharging covered entities. The contract pharmacy dispute is in active litigation across multiple circuits; track developments through PhRMA and your legal counsel for current court orders affecting your specific contract pharmacy restrictions.

If you're a commercial insurer or PBM: When a 340B hospital buys a drug at a deep discount and bills your plan at the standard allowed amount, the hospital keeps the 340B spread — sometimes 30-50% of the drug's list price. Some insurers have begun paying lower reimbursement for 340B drugs. Covered entities argue this is discriminatory; several states have enacted laws prohibiting it. Know whether your covered entity network includes 340B providers, and consult counsel on applicable state anti-discrimination laws before implementing 340B-specific reimbursement policies.

State Variations

340B is federal, but state actions affect implementation:

• Some states have enacted laws restricting insurer discrimination against 340B providers (requiring insurers to pay the same reimbursement for 340B and non-340B drugs)
• State Medicaid programs must coordinate with 340B to prevent duplicate discounts
• State pharmacy practice acts govern how contract pharmacies operate in the 340B context
• Some states have proposed their own drug pricing programs modeled on 340B principles

Implementing Regulations

• 42 CFR Part 10 — 340B Drug Pricing Program: HRSA's implementing regulations specifying the ceiling price calculation methodology and dispute resolution procedures:

  • § 10.10 — Ceiling price calculation: manufacturers must calculate the 340B ceiling price for each covered outpatient drug by NDC (National Drug Code) on a quarterly basis; the ceiling price equals the Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA) for that drug; since this is the same formula as the Medicaid rebate calculation, manufacturers can derive 340B ceiling prices from existing Medicaid rebate calculations; the quarterly recalculation requirement ensures ceiling prices reflect actual AMP movements; HRSA publishes ceiling prices through the OPAIS (Office of Pharmacy Affairs Information System) to allow covered entities to verify they are paying no more than the ceiling price
  • § 10.11 — Civil monetary penalties: any manufacturer that knowingly and intentionally charges a covered entity more than the ceiling price may be assessed a civil monetary penalty of up to $5,309 per instance (inflation-adjusted); the "knowingly and intentionally" standard is significantly higher than a strict-liability standard — inadvertent overcharges that are corrected promptly typically result in a refund requirement rather than CMP; repeated or systematic overcharging is the primary CMP target; HRSA refers to this as the manufacturer overcharge penalty; a covered entity that violates program integrity requirements (selling 340B drugs to ineligible patients, diverting to non-patients) may also face sanctions including termination from the program
  • § 10.20 — Administrative Dispute Resolution (ADR) Panel: HRSA established a formal ADR process for resolving disputes between manufacturers and covered entities about 340B compliance; the ADR Panel consists of HRSA Office of Pharmacy Affairs staff; disputes may be initiated by covered entities claiming overcharges (manufacturer charged more than ceiling price) or by manufacturers claiming diversion or duplicate discounts by covered entities
  • § 10.21 — Claims: the ADR process accepts (1) covered entity claims that a manufacturer overcharged, and (2) manufacturer claims that a covered entity has violated the diversion prohibition (selling 340B drugs to ineligible patients) or the duplicate discount prohibition (obtaining both a Medicaid rebate and a 340B discount for the same drug and patient); claims must be specific to the parties and time period; the ADR Panel reviews documentary evidence and issues a binding decision

  The Part 10 ceiling price calculation and ADR rules represent HRSA's primary formal regulatory tools in the 340B program — most 340B program administration is conducted through guidance documents, program integrity memos, and OPAIS rather than formal regulations. The ADR Panel has handled hundreds of disputes, primarily involving manufacturer allegations that covered entity contract pharmacy arrangements facilitate diversion (selling 340B drugs to ineligible patients who are not the covered entity's own patients). Recent rulemaking: 86 FR 4830 (January 2021) — the ADR rule was finalized after years of proposed rulemaking; covered entities and manufacturers have submitted hundreds of claims to the ADR panel since it became operational in 2021.

• 42 USC 256b implementing guidance — HRSA 340B Program integrity final rule (patient definition, contract pharmacy requirements, manufacturer compliance)

• OPA Notice 2020-05 — HRSA guidance on contract pharmacy arrangements under the 340B program

Pending Legislation

• HR 2372 — 340B PATIENTS Act of 2025: would require manufacturers to honor 340B discounts at contract pharmacies and prohibit conditions that limit buying or delivery, protecting access and restoring the contract pharmacy model. Status: Introduced.

See also Medicare Drug Price Negotiation for related drug pricing bills.

Recent Developments

• Contract pharmacy litigation in the federal circuits: The years-long battle over manufacturer restrictions on 340B pricing for contract pharmacies has been litigated in multiple federal circuits, with HHS losing in both the Third Circuit (Sanofi-Aventis U.S. LLC v. HHS, January 2023) and the D.C. Circuit (Novartis Pharmaceuticals Corp. v. Johnson, May 2024). Both courts held that HHS lacked authority under § 256b to compel manufacturers to deliver 340B-priced drugs to an unlimited number of contract pharmacies. The Supreme Court has not yet taken up the question. The decisions significantly reduced the practical benefit of 340B for covered entities that rely heavily on contract pharmacies (often smaller or rural providers who lack in-house pharmacy capability). HRSA is developing revised guidance on what contract pharmacy arrangements manufacturers must support under the statute.
• Trump administration and 340B reform (2025): The Trump HHS took a more manufacturer-friendly stance on 340B than the Biden administration. HRSA reduced enforcement actions under the administrative dispute resolution process. The administration's broader deregulatory posture signaled receptivity to Republican-backed 340B reforms that would add transparency requirements and tighten the patient definition — changes long sought by pharmaceutical manufacturers and opposed by hospitals and safety-net providers. Congressional reform proposals advanced in the OBBBA reconciliation discussions but the final legislation's treatment of 340B remains unclear as of May 2026.
• OBBBA and hospital reimbursement: The 2025 reconciliation legislation included hospital payment provisions that interact with 340B — changes to Disproportionate Share Hospital (DSH) payments and Medicaid managed care rules affect hospitals that are 340B covered entities. Safety-net hospitals should monitor the combined financial impact of any 340B restrictions plus DSH payment changes in the OBBBA package.
• The fundamental transparency debate: 340B's core policy tension — whether a program designed to help low-income patients has expanded into a significant hospital revenue stream — has not been resolved. Program spending estimates have grown to $50-100 billion in manufacturer-provided discounts annually. Transparency proposals requiring covered entities to report how 340B savings benefit uninsured and low-income patients have bipartisan support but have not been enacted. The IRA's Inflation Reduction Act drug pricing provisions operate separately from 340B and have added complexity to the drug pricing regulatory landscape.